APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-tau181, NfL, and GFAP) from midlife to late life compared to non-carriers.

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting APOE in human. Primary outcome: APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-tau181, NfL,

Description

APOE genotyping performed; longitudinal biomarker changes compared between ε4 carriers and non-carriers

TARGET GENE

APOE (Score: 0.621)

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

lipid metabolism

SOURCE

pmid_39068543

PRIMARY OUTCOME

APOEε4 carriers showed more rapid biomarker changes (decreasing Aβ42:Aβ40, increasing p-tau181, NfL, and GFAP) from midlife to late life compared to non-carriers.

Scoring Dimensions

Related Hypotheses (6)

TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM0.708

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia0.827

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)0.795

Competitive APOE4 Domain Stabilization Peptides0.784

APOE4-Specific Proteolytic Fragment Inhibition Therapy0.777

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.